Protein Kinase Inhibitors: all 15,038 studies that test it

Page 79 of 151. Open to participants first (2,480), then studies with results posted, then the rest; newest registration first within each.

• First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsActive, not recruitingNCT05489237Phase 1
• A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05488314Phase 1/2
• Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic DermatitisCompletedNCT05487963Phase 1/2
• Drug-drug Interactions Between AZD4205 and Itraconazole/CarbamazepineCompletedNCT05486949Phase 1
• A Study of Diet Influence of AL8326 in Chinese Healthy Adult SubjectsStatus unknownNCT05486598Phase 1
• Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand EczemaCompletedNCT05486117Phase 1
• Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCCCompletedNCT05485896Phase 2
• Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT05485350Phase 2
• Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung CancerWithdrawnNCT05481775Phase 2
• Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.TerminatedNCT05481645Phase 2
• Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT05481476Phase 2
• mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal CancerStatus unknownNCT05480280Phase 2
• Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy SubjectsCompletedNCT05478772Phase 1
• A Clinical Trial of XZP-3287 for Material BalanceStatus unknownNCT05478109Phase 1
• Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain MetastasesTerminatedNCT05477615Phase 2
• Single Dose Study To Study The Absorption, Metabolism And Excretion Of FamitinibStatus unknownNCT05473468Phase 1
• Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell CarcinomaWithdrawnNCT05472220Phase 1
• Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia AreataActive, not recruitingNCT05470413Phase 3
• An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid MalignanciesCompletedNCT05469919Phase 1
• Dalpiciclib Plus Letrozole and CapecitabineStatus unknownNCT05469750Phase 2
• Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543CompletedNCT05468749Phase 1
• A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)Active, not recruitingNCT05468697Phase 1/2
• Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543CompletedNCT05467722Phase 1
• Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy SubjectsCompletedNCT05467709Phase 1
• Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy VolunteersCompletedNCT05467696Phase 1
• A Study of Olverembatinib in the Treatment of Ph+ ALLStatus unknownNCT05466175Phase 2
• Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 InsertionActive, not recruitingNCT05466149Phase 2
• Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)CompletedNCT05465343Phase 2
• Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.SuspendedNCT05463679Phase 3
• Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve PatientsActive, not recruitingNCT05463224Phase 2
• Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 InhibitorsStatus unknownNCT05460481Phase 2
• Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLCStatus unknownNCT05458726Phase 2
• Tucatinib+Trastuzumab+Eribulin in HER2+ MBCActive, not recruitingNCT05458674Phase 2
• Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With AnlotinibStatus unknownNCT05453383Phase 2
• Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract CancerActive, not recruitingNCT05451290Phase 2
• A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyActive, not recruitingNCT05450692Phase 3
• Masitinib for the Treatment of Severe Mast Cell Activation SyndromeStatus unknownNCT05449444Phase 2
• Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal CancerStatus unknownNCT05447715Phase 2
• Study to Evaluate HT-6184 in Healthy SubjectsCompletedNCT05447546Phase 1
• A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in MyelofibrosisStatus unknownNCT05447260Phase 4
• Baricitinib for Steroid-resistant/Relapse Immune ThrombocytopeniaStatus unknownNCT05446831Phase 2
• A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of SulfasalazineCompletedNCT05445440Phase 1
• Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast CancerCompletedNCT05444998Phase 2
• TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05441956Phase 1
• Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT05441514Phase 1
• Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple SclerosisSuspendedNCT05441488Phase 3
• This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.Status unknownNCT05439499Phase 3
• This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.Status unknownNCT05438810Phase 3
• Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid TumorsActive, not recruitingNCT05438420Phase 1/2
• Pediatric Patients Aged 4 to 11 Years With APDSActive, not recruitingNCT05438407Phase 3
• A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With DermatomyositisCompletedNCT05437263Phase 3
• Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point InhibitorTerminatedNCT05436990Phase 2
• Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping MutationTerminatedNCT05435846Phase 1
• Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard TherapyActive, not recruitingNCT05435313Phase 2
• TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) PatientsActive, not recruitingNCT05434312Phase 1
• Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsCompletedNCT05433532Phase 2
• A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast CancerActive, not recruitingNCT05433480Phase 3
• Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCCActive, not recruitingNCT05433116Phase 2
• A Study of LP-168 in Healthy VolunteersCompletedNCT05432713Phase 1
• Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic DermatitisCompletedNCT05432596Phase 2
• Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy ParticipantsCompletedNCT05431634Phase 1
• Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid TumorsWithdrawnNCT05431582Phase 1
• A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT05431179Phase 3
• Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLCStatus unknownNCT05430386Phase 1
• Precise Therapy for Refractory HER2 Positive Advanced Breast CancerStatus unknownNCT05429684Phase 3
• Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid TumorsTerminatedNCT05429502Phase 1
• A Study of Linperlisib Combination With Camrelizumab in Patients With Solid TumorStatus unknownNCT05429398Phase 1
• Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038Status unknownNCT05429294Phase 2
• Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerActive, not recruitingNCT05425940Phase 3
• Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair SystemWithdrawnNCT05419817Phase 2
• A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)CompletedNCT05419401Phase 1
• Drug-drug Interactions Between DZD9008 and Itraconazole/CarbamazepineCompletedNCT05418582Phase 1
• Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 DiabetesStatus unknownNCT05416580Phase 3
• Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CMLTerminatedNCT05413915Phase 3
• Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans SyndromeStatus unknownNCT05413356Phase 2
• Assess Safety and Efficacy of VAD044 in HHT PatientsActive, not recruitingNCT05406362Phase 1/2
• Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line TherapyStatus unknownNCT05406206Phase 2
• Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AMLStatus unknownNCT05404516Phase 2
• Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory MyopathiesStatus unknownNCT05400889Phase 2
• Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerSuspendedNCT05400122Phase 1
• R-MTX-zanbrutinib in Secondary CNS LymphomaStatus unknownNCT05398224Phase 2
• Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid LeukemiaActive, not recruitingNCT05396859Phase 1
• A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction CancerStatus unknownNCT05395780Phase 2
• Regorafenib in Patients With Refractory Primary Bone TumorsCompletedNCT05395741Phase 1/2
• Clinical Study of Regorafenib and Nivolumab Plus ChemotherapyCompletedNCT05394740Phase 1/2
• Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical TrialStatus unknownNCT05392257Phase 2
• A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy VolunteersCompletedNCT05392127Phase 1
• Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular CarcinomaStatus unknownNCT05391867Not applicable
• Pembrolizumab and Lenvatinib for Resectable Hepatocellular CarcinomaActive, not recruitingNCT05389527Phase 2
• E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic MelanomaTerminatedNCT05388877Phase 1
• Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05388006Phase 2
• Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DMEActive, not recruitingNCT05387837Phase 2
• A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor BurdenActive, not recruitingNCT05387616Phase 2
• This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal AdultsActive, not recruitingNCT05386914Phase 1
• A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLCCompletedNCT05386888Phase 2
• Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous LeukemiaActive, not recruitingNCT05384587Phase 2
• Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung CancerActive, not recruitingNCT05384015Phase 2
• Onvansertib + Paclitaxel In TNBCActive, not recruitingNCT05383196Phase 1/2
• To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy VolunteersCompletedNCT05383131Phase 1
• Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)Active, not recruitingNCT05382364Phase 1

← Protein Kinase Inhibitors overview